Question 1

What is X4 Pharmaceuticals, Inc. Common Stock's WACC?

Accepted Answer

X4 Pharmaceuticals, Inc. Common Stock (XFOR) has a Weighted Average Cost of Capital (WACC) of 9.82%. This is calculated using a Cost of Equity of 9.47% (via CAPM with a beta of 1.28) and a pre-tax Cost of Debt of 11.75%, with an equity weight of 84.42% in the capital structure.

Question 2

Is X4 Pharmaceuticals, Inc. Common Stock's WACC high or low?

Accepted Answer

X4 Pharmaceuticals, Inc. Common Stock's WACC of 9.82% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is X4 Pharmaceuticals, Inc. Common Stock's WACC calculated?

Accepted Answer

X4 Pharmaceuticals, Inc. Common Stock's WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 9.47% is derived from the CAPM model using a beta of 1.28. The pre-tax Cost of Debt (Rd) is 11.75%. The capital structure is 84.42% equity and 15.58% debt.

X4 Pharmaceuticals, Inc. Common Stock (XFOR) — WACC 分析

WACC 构成

解读

X4 Pharmaceuticals, Inc. Common Stock（XFOR）WACC：9.82%

WACC计算器

X4 Pharmaceuticals, Inc. Common Stock（XFOR） WACC 解读

XFOR 公司分析

XFOR DCF 估值

继续做同行对比